Essex Investment Management Co. LLC Raises Stock Position in Evolus, Inc. (NASDAQ:EOLS)

Essex Investment Management Co. LLC lifted its stake in Evolus, Inc. (NASDAQ:EOLS) by 0.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 295,553 shares of the company’s stock after buying an additional 1,111 shares during the period. Essex Investment Management Co. LLC owned approximately 0.47% of Evolus worth $4,788,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. California State Teachers Retirement System increased its position in shares of Evolus by 1.6% during the first quarter. California State Teachers Retirement System now owns 48,109 shares of the company’s stock worth $674,000 after purchasing an additional 739 shares in the last quarter. ProShare Advisors LLC lifted its stake in Evolus by 9.9% in the first quarter. ProShare Advisors LLC now owns 11,542 shares of the company’s stock valued at $162,000 after buying an additional 1,035 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of Evolus by 9.4% in the second quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock valued at $158,000 after acquiring an additional 1,253 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Evolus by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 39,882 shares of the company’s stock worth $559,000 after acquiring an additional 1,637 shares during the last quarter. Finally, Sei Investments Co. grew its position in shares of Evolus by 9.8% during the second quarter. Sei Investments Co. now owns 33,802 shares of the company’s stock worth $367,000 after acquiring an additional 3,020 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Stock Performance

EOLS traded up $0.35 during trading on Friday, reaching $16.90. The company’s stock had a trading volume of 442,368 shares, compared to its average volume of 584,710. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -16.10 and a beta of 1.31. The company’s fifty day moving average price is $15.49 and its 200-day moving average price is $13.37. Evolus, Inc. has a 52-week low of $7.44 and a 52-week high of $17.70. The company has a debt-to-equity ratio of 6.26, a quick ratio of 2.67 and a current ratio of 2.92.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Wednesday, July 31st. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The company had revenue of $66.91 million during the quarter, compared to analysts’ expectations of $65.06 million. On average, equities analysts forecast that Evolus, Inc. will post -0.64 earnings per share for the current fiscal year.

Insider Activity at Evolus

In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the transaction, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the business’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at approximately $2,224,559.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the transaction, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.10% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Evolus in a research note on Friday, September 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a report on Monday, September 16th. Barclays boosted their price target on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Evolus in a research report on Thursday, October 3rd.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.